Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)
The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patients will receive ZS or Placebo on top of standard of care treatment with insulin and glucose.
Age
18 - 130 years
Sex
ALL
Healthy Volunteers
No
Research Site
Montgomery, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Detroit, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Royal Oak, Michigan, United States
Research Site
St Louis, Missouri, United States
Research Site
Stony Brook, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Start Date
February 13, 2018
Primary Completion Date
December 21, 2018
Completion Date
December 21, 2018
Last Updated
January 28, 2020
70
ACTUAL participants
Placebo
DRUG
Sodium Zirconium Cyclosilicate(ZS)
DRUG
Insulin
DRUG
Glucose
DRUG
Insulin
DRUG
Glucose
DRUG
Lead Sponsor
AstraZeneca
NCT06884267
NCT06366230
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03781089